Core Insights - Ensysce Biosciences has initiated a Phase 3 study of PF614, highlighting its progress towards market readiness and commitment to developing novel opioid solutions [1] - The company reported financial and operational results for the third quarter ended September 30, 2025, indicating a productive quarter despite challenges in drug development [1] Financial Performance - Ensysce's financial results for Q3 2025 were disclosed, reflecting the company's ongoing efforts to advance its programs [1] - The company has secured preferred stock financing to support further program advancement [1] Operational Highlights - The initiation of the Phase 3 study of PF614 is a significant milestone for Ensysce, emphasizing its focus on severe pain therapeutics designed to minimize abuse and overdose risks [1] - Dr. Lynn Kirkpatrick, CEO, noted the productivity of the quarter amidst the complexities of drug development [1]